GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of why does nobody talk about biopsy — 55 comments in the full submission. View in context.
1.2k
c/survodutide·submitted 1 year ago by u/titration_marshal

why does nobody talk about biopsy

Questionbranch of 5 comments

Right, the glucagon question again, but with numbers this time. I have 18 data points over 20 weeks. The pattern is consistent enough that I do not think it is chance, and boring enough that nobody is going to screenshot it, which is usually a good sign. The thing I would flag for anyone new: the effect I am…

Read the full submission and all 55 comments →

This branch

5 comments, started 1 year ago
u/diego_szabo251 points·1 year ago

glucagon co-agonism has a different safety story

replysharereportpermalink
u/rafael_sjoberg118 points·1 year ago

glucagon co-agonism has a different safety story

Adding to this: hepatic fat is doing more work than the comment implies.

replysharereportpermalink
u/titration_marshalOPmod · c/semaglutide60 points·1 year ago

Yeah, glucagon co-agonism is genuinely different.

replysharereportpermalink
u/renzo_asante205 points·1 year ago

This is correct. Do not generalise from tirzepatide.

replysharereportpermalink
u/liver_enzyme_liz122 points·1 year ago

Disagree but this is the good kind of wrong — it is specific enough to be checked.

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.